Pandan tout mwa Me an Santé9 ap envite ou suiv sou @radiomagik9 yon emisyon sou sante fanm ak timoun. Demen madi 6 me 2025 a pati 9h am nap reprann emisyon sou kansè kòl matris sou @radiomagik9 avèk envite Dr Joseph Bernard Junior @Oncodoc_ht .
MECCA trial:
💊💊💊Despite past views of endocrine therapy as antagonistic, Metronomic capecitabine + AI significantly improves PFS (20.9 vs. 11.9 mo, HR 0.58) & OS in HR+/HER2- MBC. @OncoAlert@JCO_ASCO
https://t.co/V8LCdUBzgw
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
"Among patients who had been alive and progression-free at 3 years, 10-year melanoma-specific survival was 96% with nivolumab plus ipilimumab, 97% with nivolumab, and 88% with ipilimumab"
https://t.co/mANXG1hlt5